When compared to the mutation status obtained with FFPE tumor samples, 14 out of 17 (82%) cases showed agreement for BRAFV600 (sensitivity 67%, and specificity 75%) and 14 out of 17(82%) for NRAS (sensitivity 40%, and specificity 100%). Here, NRAS is linked to neoplasm.